Disparities in hormone replacement therapy use by socioeconomic status in a primary care population

Journal of Community Health

Volumn 26, Issue 1, 2001, Pages 39-50

  Finley, Christine ^a   Gregg, Edward W ^a   Solomon, Laura J ^b   Gay, Elaine ^b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

Hormone replacement therapy; Physician advice; Socioeconomic status

Indexed keywords

AGED; ARTICLE; CROSS-SECTIONAL STUDY; DECISION MAKING; ESTROGEN THERAPY; FEMALE; HEALTH BEHAVIOR; HUMAN; MIDDLE AGED; PATIENT ATTITUDE; POSTMENOPAUSE; PRIMARY HEALTH CARE; QUESTIONNAIRE; RISK FACTOR; SOCIOECONOMICS; STATISTICS; UNITED STATES; UTILIZATION REVIEW;

AGED; CROSS-SECTIONAL STUDIES; DECISION MAKING; ESTROGEN REPLACEMENT THERAPY; FEMALE; HEALTH BEHAVIOR; HUMANS; MIDDLE AGED; NEW YORK; PATIENT ACCEPTANCE OF HEALTH CARE; POSTMENOPAUSE; PRIMARY HEALTH CARE; QUESTIONNAIRES; RISK FACTORS; SOCIOECONOMIC FACTORS; VERMONT;

EID: 0035257451     PISSN: 00945145     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026537114638     Document Type: Article

References (20)

1. Cauley JA, Seeley DG, Ensrud KE, Ettinger B, Black DM, Cummings SR Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995;122:9-16.
2. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-1593.
3. Ettinger B, Genant HK, Cann CE. Long-term estrogen replacement therapy prevent bone loss and fractures. Ann Intern Med 1985; 102:319-324.
4. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117:1016-1037.
5. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335;453-461.
6. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten year follow-up from the Nurses' Health Study. N Engl J Med 1991;325:756-762.
7. U.S. Preventive Services Task Force. Postmenopausal Hormone Prophylaxis. Guide to clinical preventive services, 2nd ed. Williams and Wilkins, Inc., 1996.
8. Nawaz H, Katz DL. American College of Preventive Medicine Practice Policy Statement. Perimenopausal and postmenopausal hormone replacement therapy. Am J Prev Med 1999; 17:250-254.
9. Brett KM, Madans JH. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am J Epidemiol 1997; 145:536-45.
10. Feinstein JS. The relationship between socioeconomic status and health: A review of the literature. Milb Quart 1993; 71:279-322.
11. Leveille SG, LaCroix AZ, Newton KM, Keenan NL. Older women and hormone replacement therapy: Factors influencing late life initiation. J Am Geriatr Soc 1997; 45:1496-1500.
12. Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999; 130:545-53.
13. Solberg LI, Brekke ML, Kottke TE. Are physicians less likely to recommend preventive services to low-SES patients? Preventive Medicine 1997; 26:350-357.
14. Cauley JA, Cummings SR, Black DM, Mascioli SR, Seeley DG. Prevalence and determinants of estrogen therapy in elderly women. Am J Obstet Gynecol 1990; 163:1438-44.
15. Calle EE, Flanders WD, Thun MJ, Martin LM. Demographic predictors of mammography and pap smear screening in US women. Am J Public Health 1993; 83:53-60.
16. Rimer BK. Mammography use in the U.S.: trends and the impact of interventions. Ann Behav Med 1994; 16:317-326.
17. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, re users healthier than nonusers? Am J Epidemiol 1996; 143:971-978.
18. Barrett-Conner E. Postmenopausal estrogen and prevention bias. Ann Intern Med 1991; 115: 455-6.
19. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995; 273:199-208.
20. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-13.